| Literature DB >> 21253584 |
Tegan N Lavoie1, Byung Ha Lee, Cuong Q Nguyen.
Abstract
Sjögren's syndrome (SjS) is a complex chronic autoimmune disease of unknown etiology which primarily targets the exocrine glands, resulting in eventual loss of secretory function. The disease can present as either primary SjS or secondary SjS, the latter of which occurs concomitantly with another autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, or primary biliary cirrhosis. Current advancements in therapeutic prevention and treatment for SjS are impeded by lack of understanding in the pathophysiological and clinical progression of the disease. Development of appropriate mouse models for both primary and secondary SjS is needed in order to advance knowledge of this disease. This paper details important features, advantages, and pitfalls of current animal models of SjS, including spontaneous, transgenic, knockout, immunization, and transplantation chimera mouse models, and emphasizes the need for a better model in representing the human SjS phenotype.Entities:
Mesh:
Year: 2010 PMID: 21253584 PMCID: PMC3018660 DOI: 10.1155/2011/549107
Source DB: PubMed Journal: J Biomed Biotechnol ISSN: 1110-7243
Important criterion for an ideal primary SjS mouse model.
| Features | |
|---|---|
| Etiology | Unknown (possible viral exposure) |
| Clinical | Xerostomia Keratoconjunctivitis sicca |
| Histological | Polyclonal lymphocytic infiltrations in the salivary and lacrimal glands Lymphocytic focus, >50 mononuclear cells/mm2 (CD4+ > CD8+)Monoclonal B cell proliferation Progressive destruction of the acinar and ductal cells |
| Serological | Hypergammaglobulinemia Anti-SSA/Ro and anti-SSB/La autoantibodiesAnti- |
| Additional organ involvement | Heart, blood vessels, lungs, liver, pancreas, stomach, kidneys, bladder, thyroid gland (secondary SjS) |
| Immunobiology | Diminished apoptosis of lymphocytes Abnormal MHC expression, H2+-glandular ductal epithelium Epithelial cell expression of Fas/FasL |
| Other | 9 : 1 female : male ratio Disease presents in absence of other rheumatic diseases |
Primary and secondary SjS mouse models.
| Type of SjS | Mouse Model | Secondary to |
|---|---|---|
| Primary | Aec1Aec2 | — |
| NOD.B10- | — | |
| NFS/sld | — | |
| IQI/Jic | — | |
| CAII immunization | — | |
| PI3K K.O. | — | |
| ID3 K.O. | — | |
| Ar K.O. | — | |
| Ro immunization | — | |
| Aly/aly | — | |
| Secondary | NOD | Autoimmune diabetes |
| NOD. | Autoimmune thyroiditis | |
| MRL/lpr | RA, SLE | |
| GVHR | SLE | |
| BAFF Tg | SLE | |
| IL-12 Tg | SLE | |
| IL-14 | SLE | |
| MCMV | SLE | |
| HTLV-1 tax Tg | RA [ | |
| TGF- | SLE [ | |
| IL-6 TgIL-10 Tg | PBC [ | |
| TSP-1 K.O. | IBS | |
K.O.: knockout; Tg: transgenic; SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; PBC: primary biliary cirrhosis; IBS: inflammatory bowel disease.
Features of common spontaneous and transgenic mouse models for SjS.
| Characteristic | Autoantibodies | Sjögren's syndrome patient | Spontaneous mouse model | Transgenic mouse model | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NOD | NZB/ | MRL/ | NFS/ | IQI/ | BAFF | IL-6 | IL-10 | IL-12 | IL-14 | ||||||
| Anti-Ro/SS-A, Anti-La/SS-B | Yes | Yes | No | No | Yes | Yes | No | — | — | No | — | No | Yes | Yes | |
| Anti-DNA (ANAs) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | — | — | Yes | — | — | Yes | — | |
| Anti- | Yes | Yes | — | — | Yes | Yes | — | — | — | — | — | — | — | — | |
| Anti- | Yes | Yes | Yes | Yes | Yes | — | — | — | — | — | — | — | — | — | |
| Anti-type3 muscarinic Ach receptor | Yes | Yes | Yes | Yes | Yes | — | — | — | — | — | — | — | — | — | |
| Leukocytic infiltrate | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Time of onset (weeks) | 12 | 10 | 16 | 8 | 16 | 8 | 24 | 24 | 52 | 2 | 8 | <16 | 48 | ||
| Dacryoadenitis | Yes | Yes | Yes | Yes | Yes | Yes | Yes | — | Yes | — | — | Yes | Yes | — | |
| Sialadenitis | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | — | Yes | Yes | Yes | |
| Loss secretory function | Yes | Var | Yes | Var | No | Yes | — | — | — | Yes | — | Yes | Var | Var | |
| - Time of onset (weeks) | 20 | 19 | 24 | — | 72 | — | — | — | 52 | — | 8 | 16 | 12 | ||
| - Target organ | S, L | S, L | L | — | S, L | — | — | — | S | — | S, L | S, L | S | ||
| Proinflammatory cytokine product | Yes | Yes | Yes | Yes | Yes | Yes | Yes | — | — | — | Yes | Yes | Yes | Yes | |
Var: variable, male, and female mice differ, –: Not determined, S: Salivary glands, L: Lacrimal glands.
Features of common knockout, immunization, infection, and transplantation chimera mouse models for SjS.
| Characteristic | Autoantibodies | Sjögren's syndrome patient | Knockout (KO) mouse model | Immunization mouse model | Infectionmouse model | Transplantation chimeras | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PI3K | TGF- | TSP-1 | Ar | Ro | CMV | GVHR | |||||
| Anti-Ro/SS-A, Anti-La/SS-B | Yes | Yes | Yes | No | Yes | — | — | Yes | Yes | — | |
| Anti-DNA (ANAs) | Yes | — | — | Yes | — | No | — | — | — | Yes | |
| Anti- | Yes | — | — | — | — | Yes | — | — | — | — | |
| Anti- | Yes | — | — | — | — | — | — | — | — | — | |
| Anti-type3 muscarinic Ach receptor | Yes | — | — | — | — | — | — | — | — | — | |
| Leukocytic infiltrate | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| - Time of onset (weeks) | 8 | 8 | 1 | 24 | 48 | — | 16 | 4 | 28 | ||
| Dacryoadenitis | Yes | Yes | Yes | — | Yes | — | Yes | — | — | — | |
| Sialadenitis | Yes | Yes | Yes | Yes | — | Yes | Yes | Yes | Yes | Yes | |
| Loss of secretory function | Yes | Yes | Yes | Yes | Yes | — | — | Yes | Yes | — | |
| - Time of onset (weeks) | 8 | <8 | >1 | 24 | — | — | 16 | 4 | — | ||
| - Target organ | S, L | S, L | S | L | — | — | S | S | — | ||
| Proinflammatory cytokine product | Yes | — | Yes | Yes | Yes | — | — | — | — | — | |
Var: variable, male, and female mice differ, –: Not determined, S: Salivary glands, L: Lacrimal glands.